# Sitryx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sitryx-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.sitryx.com
- Total disclosed funding: $67M
- Latest round: Series A (Sep 27, 2023)
- Investors on record: 6

## About

Sitryx Therapeutics Limited is an innovative biopharmaceutical company focused on developing therapies that rebalance the immune system to combat chronic autoimmune and inflammatory diseases.Founded in 2018, Sitryx Therapeutics Limited operates from its headquarters in Oxford, UK. The company specializes in immunometabolism, targeting specific metabolic pathways in immune cells. Paul Tak, the founder, has a history of involvement in the biopharmaceutical sector. In its recent funding round, the company raised USD 39.00 mn in Series A funding on September 27, 2023, with participation from investors including Eli Lilly & Company and GSK Venture Fund. This funding will support the advancement of their innovative therapies.Sitryx focuses on developing disease-modifying therapies aimed at correcting immune cell dysfunction. Their key product, SIT-047, is a novel oral MTHFD2 inhibitor, currently nominated for clinical development in psoriatic arthritis, with trials expected to advance by May 2025. The company's offerings target chronic conditions such as psoriatic arthritis and atopic dermatitis, serving biopharmaceutical partners and healthcare providers worldwide, particularly in North America, Europe, and Asia.Sitryx generates revenue through collaborations, notably a deal with Eli Lilly valued at up to USD 1.1 bn, which includes development milestones and tiered royalties. Their business model primarily involves B2B transactions with pharmaceutical firms and research institutions, focusing on milestone payments, royalties on product sales, and potential licensing agreements for their proprietary therapies.Following the recent raising of USD 39.00 mn in Series A funding on September 27, 2023, Sitryx plans to utilize these resources to further develop its immunometabolism-targeting treatments. The company aims to launch SIT-047 and expand its presence in new markets, specifically targeting regions in North America and Europe for future commercialization of its therapies.

## Funding rounds

- Series A, Sep 27, 2023, $39M — Sofinnova Partners, SV Health Investors, Longwood Fund, Eli Lilly & Company, Oxford Sciences Enterprises, GSK Venture Fund
- Series A, Jan 23, 2018, $28M — Sofinnova Partners, SV Health Investors, Longwood Fund, GSK Venture Fund

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- GSK Venture Fund — Series A
- Eli Lilly & Company — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A